Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-22-005261
Filing Date
2022-08-02
Accepted
2022-08-02 15:07:18
Documents
46
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q coeptis_i10q-063022.htm   iXBRL 10-Q 743725
2 CERTIFICATION coeptis_ex3101.htm EX-31.1 8164
3 CERTIFICATION coeptis_ex3102.htm EX-31.2 8186
4 CERTIFICATION coeptis_ex3201.htm EX-32.1 2379
5 CERTIFICATION coeptis_ex3202.htm EX-32.2 2309
  Complete submission text file 0001683168-22-005261.txt   3880262

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE coep-20220630.xsd EX-101.SCH 30933
7 XBRL CALCULATION FILE coep-20220630_cal.xml EX-101.CAL 41929
8 XBRL DEFINITION FILE coep-20220630_def.xml EX-101.DEF 117818
9 XBRL LABEL FILE coep-20220630_lab.xml EX-101.LAB 226905
10 XBRL PRESENTATION FILE coep-20220630_pre.xml EX-101.PRE 186186
40 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_i10q-063022_htm.xml XML 545813
Mailing Address 105 BRADFORD RD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD RD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Inc. (Filer) CIK: 0001819663 (see all company filings)

EIN.: 843998117 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56194 | Film No.: 221128320
SIC: 2834 Pharmaceutical Preparations